Wanted: “Imaginative and Original Thoughts” On Coverage With Evidence Development
This article was originally published in RPM Report
Executive Summary
The Centers for Medicare & Medicaid Services is revisiting its policy on Coverage with Evidence Development. Here is how two key officials from CMS’ Coverage & Analysis Group described their thinking during a conversation with The RPM Report as part of the FDA/CMS Summit for Biopharma Executives in December.
You may also be interested in...
Coverage With Evidence Development and Expedited Approvals: Policy Proposals For FDA and CMS
Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.